ATE394114T1 - Somatostatin-antagonisten - Google Patents

Somatostatin-antagonisten

Info

Publication number
ATE394114T1
ATE394114T1 AT02728410T AT02728410T ATE394114T1 AT E394114 T1 ATE394114 T1 AT E394114T1 AT 02728410 T AT02728410 T AT 02728410T AT 02728410 T AT02728410 T AT 02728410T AT E394114 T1 ATE394114 T1 AT E394114T1
Authority
AT
Austria
Prior art keywords
somatostatin antagonists
somatostatin
antagonists
Prior art date
Application number
AT02728410T
Other languages
English (en)
Inventor
David Coy
William Murphy
Walajapet Rajeswaran
Original Assignee
Univ Tulane
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Tulane filed Critical Univ Tulane
Application granted granted Critical
Publication of ATE394114T1 publication Critical patent/ATE394114T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/31Somatostatins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02728410T 2001-03-08 2002-03-05 Somatostatin-antagonisten ATE394114T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27430801P 2001-03-08 2001-03-08

Publications (1)

Publication Number Publication Date
ATE394114T1 true ATE394114T1 (de) 2008-05-15

Family

ID=23047655

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02728410T ATE394114T1 (de) 2001-03-08 2002-03-05 Somatostatin-antagonisten

Country Status (16)

Country Link
US (3) US7378488B2 (de)
EP (1) EP1372688B1 (de)
JP (3) JP4204322B2 (de)
AR (1) AR035942A1 (de)
AT (1) ATE394114T1 (de)
AU (1) AU2002258465B2 (de)
CA (1) CA2439498A1 (de)
CZ (1) CZ299362B6 (de)
DE (1) DE60226419D1 (de)
DK (1) DK1372688T3 (de)
ES (1) ES2306766T3 (de)
HU (1) HUP0401535A3 (de)
NO (1) NO20033911L (de)
PL (1) PL362838A1 (de)
RU (2) RU2263678C2 (de)
WO (1) WO2002072602A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2425804A1 (en) * 2000-10-20 2002-04-25 The Administrators Of The Tulane Educational Fund Urotensin-ii agonists and antagonists
CZ299362B6 (cs) 2001-03-08 2008-07-02 The Administrators Of The Tulane Educational Fund Antagonisté somatostatinu
EP1397150A4 (de) * 2001-04-09 2005-01-26 Administrators Ofthe Tulane Ed Somatostatin-agonisten
EP1522311A1 (de) 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verwendung von Somatostatin oder seine Derivate zur Herstellung eines Medikamentes zur Regulierung der Ovarialfollikelnreserve bei der nicht menopausierte Frau
WO2006063465A1 (en) * 2004-12-15 2006-06-22 Diamedica Inc. Treatment of insulin resistance by modulating somatostatin using somatostatin receptor antagonists
CA2666642C (en) 2006-10-16 2015-11-17 The Salk Institute For Biological Studies Receptor(sstr2)-selective somatostatin antagonists
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
EP2168983A1 (de) * 2008-09-30 2010-03-31 Ipsen Pharma Neue Oktapeptid-Verbindungen und ihr therapeutischer Einsatz
WO2010050516A1 (ja) * 2008-10-29 2010-05-06 株式会社カネカ L-アミノ酸の製造方法
EP2399931A1 (de) * 2010-06-22 2011-12-28 Ipsen Pharma S.A.S. Neue Oktapeptid-Verbindungen und ihr therapeutischer Einsatz
AU2017217271C1 (en) 2016-02-09 2021-08-05 Cdrd Ventures Inc. Somatostatin receptor antagonist compounds and methods of using the same
WO2021111503A1 (ja) * 2019-12-02 2021-06-10 花王株式会社 光吸収層及びその製造方法、分散液、光電変換素子、並びに太陽電池

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0034567B1 (de) * 1980-02-14 1984-11-07 Sandoz Ag Verfahren zur Totalsynthese von Cyclosporinen und neue Cyclosporine
EP0278158A3 (de) 1986-11-12 1990-05-23 Merck & Co. Inc. Renin-Inhibitoren enthaltende Phenylalanin-Histidin-Stellvertreter
JPS63146850A (ja) 1986-11-12 1988-06-18 メルク エンド カムパニー インコーポレーテツド フエニルアラニル−ヒスチジン代用成分を有するレニン阻害剤
EP0273696A2 (de) 1987-01-02 1988-07-06 Merck & Co. Inc. Renin-Inhibitoren, in denen Histidin ersetzt ist
CH679045A5 (de) 1987-06-29 1991-12-13 Sandoz Ag
JPS6426599U (de) 1987-08-10 1989-02-15
WO1989007450A1 (en) 1988-02-10 1989-08-24 Abbott Laboratories Lhrh analogs
ES2091907T3 (es) * 1989-12-08 1996-11-16 Univ Tulane Analogos octapeptidos de somatostina con una threonina en la sexta posicion.
US7223833B1 (en) * 1991-05-24 2007-05-29 Isis Pharmaceuticals, Inc. Peptide nucleic acid conjugates
WO1993003058A2 (en) 1991-07-01 1993-02-18 University Technologies International Inc. NON-DESENSITIZING ANALOGS OF GnRH AND OTHER BIOLOGICALLY ACTIVE LIGANDS
JP3480848B2 (ja) * 1992-06-19 2003-12-22 タカラバイオ株式会社 環状ペプチドの合成方法
US5569741A (en) * 1992-07-27 1996-10-29 Biomeasure, Inc. Cyclic octapeptide neuromedin B receptor antagonists
EP0788509B1 (de) 1993-08-09 2003-05-28 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Therapeutisch wirksame peptidderivate
JP3759748B2 (ja) * 1993-12-23 2006-03-29 ノボ ノルディスク アクティーゼルスカブ 成長ホルモン放出性を有する化合物
GB9402767D0 (en) 1994-02-14 1994-04-06 Sandoz Ltd Improvements in or relating to organic compounds
US5696230A (en) * 1994-08-31 1997-12-09 The Board Of Regents Of The University Of Nebraska High-affinity response-selective C-terminal analogs of C5a anaphylatoxin
US5750499A (en) * 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
US5846934A (en) * 1996-02-20 1998-12-08 American Cyanamid Company Pure somatostatin antagonist and methods of use thereof
US6355613B1 (en) * 1996-07-31 2002-03-12 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
AU3215597A (en) 1996-08-30 1998-03-19 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
AU4133997A (en) * 1996-09-12 1998-04-02 Yarom Cohen Pharmaceutical composition for the treatment of syndrome x of reaven
ATE330966T1 (de) * 1996-12-04 2006-07-15 Sod Conseils Rech Applic Somatostatin-antagonisten
US6887470B1 (en) * 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DE60232203D1 (de) 2001-03-06 2009-06-10 Il Consorzio Ferrara Richerche Verfahren zur Modulation der Proliferation von Schilddrüsenkrebszellen
CZ299362B6 (cs) 2001-03-08 2008-07-02 The Administrators Of The Tulane Educational Fund Antagonisté somatostatinu
EP1397150A4 (de) 2001-04-09 2005-01-26 Administrators Ofthe Tulane Ed Somatostatin-agonisten

Also Published As

Publication number Publication date
RU2005117614A (ru) 2006-11-20
HUP0401535A3 (en) 2009-07-28
JP2006342171A (ja) 2006-12-21
CZ20032281A3 (cs) 2004-01-14
HUP0401535A2 (hu) 2004-12-28
NO20033911L (no) 2003-10-29
CA2439498A1 (en) 2002-09-19
WO2002072602A2 (en) 2002-09-19
WO2002072602A3 (en) 2003-03-20
EP1372688A2 (de) 2004-01-02
AR035942A1 (es) 2004-07-28
ES2306766T3 (es) 2008-11-16
DE60226419D1 (de) 2008-06-19
DK1372688T3 (da) 2008-08-25
AU2002258465B2 (en) 2006-01-19
JP2004532824A (ja) 2004-10-28
JP2008255120A (ja) 2008-10-23
RU2263678C2 (ru) 2005-11-10
RU2003129807A (ru) 2005-03-20
JP4204322B2 (ja) 2009-01-07
PL362838A1 (en) 2004-11-02
US20040181032A1 (en) 2004-09-16
US7408024B2 (en) 2008-08-05
US20080020970A1 (en) 2008-01-24
US20080171853A1 (en) 2008-07-17
RU2328504C2 (ru) 2008-07-10
CZ299362B6 (cs) 2008-07-02
EP1372688B1 (de) 2008-05-07
NO20033911D0 (no) 2003-09-04
US7378488B2 (en) 2008-05-27
EP1372688A4 (de) 2006-06-14

Similar Documents

Publication Publication Date Title
ATE402148T1 (de) Substituierte pyridinylamine
IS7016A (is) Ný 4-anilínókínólín-3-karboxamíð
ATE524462T1 (de) C5-modifizierte indazolylpyrrolotriazine
DE50103741D1 (de) Welle-Nabe-Verbindung
DE50206892D1 (de) Substituierte imidazotriazinone
ATE335486T1 (de) Hydrazono-malonitrile
NO20034497D0 (no) Somatostatin agonister
NO20014597D0 (no) Fremgangsmåte
DE60222693D1 (de) Nk1-antagonisten
DK1373228T3 (da) Substituerede fluoralkoxyphenylsulfonylurinstoffer
ATE394114T1 (de) Somatostatin-antagonisten
ATE355059T1 (de) Isoxazolopyridinone
DK1406858T3 (da) Substituerede 4-aminocyklohexanoler
DE50201862D1 (de) Messwandler
DE50214673D1 (de) Schnittstelle
DE50212426D1 (de) Bohrwerkzeug
ATA18372001A (de) Gelenksbolzenbaueinheit
PL362793A1 (pl) Antagoniści reseptorów histaminowych
ATE319694T1 (de) Phenylalkyne
DE50108381D1 (de) Synchronisierschaltungsanordnung
DE10295006D2 (de) Bauwerksabdichtung
DE60216967D1 (de) Substituierte cyclohexanderivate
ATE405973T1 (de) Steckverbindung
ATA2892002A (de) Beschlag
AT500276B8 (de) Radschwenksystem

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1372688

Country of ref document: EP

REN Ceased due to non-payment of the annual fee